Peroxisome proliferator-actived receptor-γ ligand troglitazone induces apoptosis in renal cell carcinoma
YANG Feng guang 1, ZHANG Zhi wen 2△ , XIN Dian qi 1, SHI Chang jin 1, WU Xue qing 1, LIU Wu jiang 1,GUO Ying lu 1, WU Jie ping 1 (1.Department of Urology,Peking University First Hospital; Peking University Institute of Urology; 2. Department of Physiology,Peking University School of Basic Medical Sciences,Beijing 100083,China)
Objective: To investigate the expression of peroxisome proliferator actived receptor γ (PPAR γ)and the inducement of apoptosis by PPAR γ ligand in renal cell carcinoma(RCC) derived cell lines.Methods:RT-PCR and Western blot analysis were performed to determined the expression of PPAR γ mRNA and protein in two RCC derived cell lines(786 O and A498) and two normal kidney(NK) derived cell lines(HK 2 and HMCC). Two RCC cell lines were treated with 50 μmol/L troglitazoned for and evaluated for the effects of antidiabetic thiazolidinediones (TZDs) on the cells apoptosis by fluorescence microscopy and DNA ladder assay.The mutative expressions of Bcl 2 and Bax before and after TZDs treatment were also performed by western blot analysis. Results: The expression of PPAR γ was observed to be stronger in 786 O and A498 cells than in HK 2 and HMCC cells by RT-PCR and Western blot analysis. Treated with 50 μmol/L troglitazone (for 48 h) it induced typical apoatosis in 786 O and A498 cells. After treatment, a decrease in Bcl 2 expression in RCC cells was observed by Western blot analysis,and the expression of Bax,however,was up regulated.Conclusion: The results reveal that troglitazone has the tumor suppressive effect on RCC cells. High affinity PPAR γ ligands (TZDs) may be the candidates for a novel approach to the treatment of this refractory neoplasm.
【CateGory Index】： R737.11